B. Riley Issues Pessimistic Outlook for Verastem Earnings

Verastem, Inc. (NASDAQ:VSTM) – B. Riley decreased their Q2 2025 earnings per share estimates for shares of Verastem in a research note issued to investors on Monday, April 28th. B. Riley analyst K. Patel now expects that the biopharmaceutical company will earn ($0.56) per share for the quarter, down from their prior estimate of ($0.53). B. Riley has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Verastem’s current full-year earnings is ($3.02) per share. B. Riley also issued estimates for Verastem’s Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.98) EPS, FY2026 earnings at ($1.21) EPS and FY2028 earnings at $0.99 EPS.

Several other equities research analysts have also commented on VSTM. Guggenheim boosted their price objective on Verastem from $13.00 to $14.00 and gave the stock a “buy” rating in a research note on Monday, March 24th. HC Wainwright raised their price objective on Verastem from $7.00 to $10.00 and gave the company a “buy” rating in a report on Monday, March 24th. Mizuho lowered their target price on shares of Verastem from $9.00 to $8.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 9th. Jefferies Financial Group started coverage on shares of Verastem in a research report on Thursday, April 10th. They issued a “buy” rating and a $15.00 target price for the company. Finally, Royal Bank of Canada dropped their price objective on shares of Verastem from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Friday, March 21st. One equities research analyst has rated the stock with a sell rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $13.89.

Verastem Stock Down 0.8 %

Shares of NASDAQ VSTM opened at $7.43 on Thursday. The firm has a market cap of $382.57 million, a price-to-earnings ratio of -2.33 and a beta of 0.57. The company’s 50-day simple moving average is $6.19 and its 200-day simple moving average is $5.29. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 2.77. Verastem has a 52-week low of $2.10 and a 52-week high of $13.52.

Verastem (NASDAQ:VSTM) last released its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.57).

Institutional Trading of Verastem

A number of hedge funds and other institutional investors have recently modified their holdings of the business. State Street Corp increased its position in shares of Verastem by 18.2% during the third quarter. State Street Corp now owns 424,264 shares of the biopharmaceutical company’s stock valued at $1,269,000 after acquiring an additional 65,265 shares during the last quarter. Barclays PLC raised its position in Verastem by 546.7% in the third quarter. Barclays PLC now owns 55,708 shares of the biopharmaceutical company’s stock valued at $167,000 after purchasing an additional 47,094 shares during the period. Geode Capital Management LLC lifted its stake in Verastem by 67.6% during the third quarter. Geode Capital Management LLC now owns 890,599 shares of the biopharmaceutical company’s stock worth $2,663,000 after purchasing an additional 359,060 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Verastem by 55.4% during the third quarter. JPMorgan Chase & Co. now owns 16,878 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 6,016 shares during the period. Finally, SG Americas Securities LLC grew its stake in shares of Verastem by 152.8% in the fourth quarter. SG Americas Securities LLC now owns 36,515 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 22,071 shares in the last quarter. 88.37% of the stock is owned by institutional investors and hedge funds.

Verastem Company Profile

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.